Orexo and Boehringer Ingelheim Extend Their Research Collaboration
The collaboration is focused on the development of a drug which specifically inhibits the enzyme prostaglandin (PG) E synthase (mPGES) to reduce the production of PGE2, an endogenous substance that is central to various inflammatory processes. Thanks to its selective inhibition, the drug could have fewer side effects than existing pain medications, such as the NSAIDs.
Under the terms of the agreement, Boehringer Ingelheim will continue research funding to Orexo in the OX-MPI project. Boehringer Ingelheim holds exclusive rights to all further compound development and marketing, except in the Nordic and Baltic regions, where Boehringer Ingelheim and Orexo will co-promote potential products developed.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.